Johnson & Johnson $JNJ Shares Sold by Salomon & Ludwin LLC

Salomon & Ludwin LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 4.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,695 shares of the company’s stock after selling 207 shares during the quarter. Salomon & Ludwin LLC’s holdings in Johnson & Johnson were worth $730,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. Brighton Jones LLC raised its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the period. Wealth Group Ltd. purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $218,000. GAMMA Investing LLC raised its stake in shares of Johnson & Johnson by 48.0% in the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock valued at $7,215,000 after acquiring an additional 14,118 shares during the period. Monte Financial Group LLC raised its stake in shares of Johnson & Johnson by 1.3% in the 1st quarter. Monte Financial Group LLC now owns 36,636 shares of the company’s stock valued at $5,769,000 after acquiring an additional 464 shares during the period. Finally, Weaver Capital Management LLC raised its stake in shares of Johnson & Johnson by 30.9% in the 1st quarter. Weaver Capital Management LLC now owns 12,261 shares of the company’s stock valued at $2,033,000 after acquiring an additional 2,891 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.3%

Shares of NYSE:JNJ opened at $193.78 on Tuesday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48. The company’s 50 day moving average is $180.89 and its two-hundred day moving average is $165.18. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a market cap of $466.68 billion, a PE ratio of 18.70, a P/E/G ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The company had revenue of $24.02 billion for the quarter. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Royal Bank Of Canada reiterated an “outperform” rating and set a $209.00 target price on shares of Johnson & Johnson in a report on Friday, October 10th. The Goldman Sachs Group increased their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. UBS Group increased their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a report on Tuesday, October 14th. Finally, Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $200.06.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.